Investigation of Molecular Mechanisms of S-1, Docetaxel and Cisplatin in Gastric Cancer With a History of Helicobacter Pylori Infection Publisher Pubmed



Kashani SF¹ ; Abedini Z² ; Darehshouri AF² ; Jazi K³ ; Bereimipour A^{4, 5} ; Malekraeisi MA⁶ ; Javanshir HT¹ ; Mahmoodzadeh H¹ ; Hadjilooei F¹ Show Affiliations
Source: Molecular Biotechnology Published:2024

Abstract

Gastric cancer rates and fatality rates have not decreased. Gastric cancer treatment has historically included surgery (both endoscopic and open), chemotherapy, targeted therapy, and immunotherapy. One of the aggravating carriers of this cancer is Helicobacter pylori infection. Various drug combinations are used to treat gastric cancer. However, examining the molecular function of these drugs, depending on whether or not there is a history of Helicobacter pylori infection, can be a better help in the treatment of these patients. This study was designed as bioinformatics. Various datasets such as patients with gastric cancer, with and without a history of H. pylori, and chemotherapy drugs cisplatin, docetaxel, and S-1 were selected. Using Venn diagrams, the similarities between gene expression profiles were assessed and isolated. Then, selected the signal pathways, ontology of candidate genes and proteins. Then, in clinical databases, we confirmed the candidate genes and proteins. The association between gastric cancer patients with and without a history of H. pylori with chemotherapy drugs was investigated. The pathways of cellular aging, apoptosis, MAPK, and TGFβ were clearly seen. After a closer look at the ontology of genes and the relationship between proteins, we nominated important biomolecules. Accordingly, NCOR1, KIT, MITF, ESF1, ARNT2, TCF7L2, and KRR1 proteins showed an important role in these connections. Finally, NCOR1, KIT, KRR1, and ESF1 proteins showed a more prominent role in the molecular mechanisms of S-1, Docetaxel, and Cisplatin in gastric cancer associated with or without H. pylori. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.